로딩 중…
지수 로딩 중…
Immatics N.V.
IMTX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
DE
DE$8.82+2.08%
2026-09-17
Financials
Valuation Metrics
Immatics N.V.'s Market Cap is $1.21B. At end of 2025 it was $584M. Ranked #2365 of 3,121 in US market (top 76%), #955 of 1,463 on NASDAQ (top 65%), #180 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.21B | US#2,365/3,121 Sec#180/266 |
| Revenue | $47M | US#2,779/3,121 Sec#152/266 |
| Net Income | $-233M | US—/3,121 Sec—/266 |
| Total Assets | $570M | US#2,718/3,121 Sec#146/266 |
| Net Assets | $469M | US#2,274/3,121 Sec#113/266 |
| Value | ||
| P/B | 2.57x | US#1,573/3,121 Sec#74/266 |
| P/S | 25.58x | US#2,874/3,121 Sec#148/266 |
| FCF Yield | -19.68% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -49.73% | US#2,679/3,121 Sec#156/266 |
| ROA | -40.91% | US#2,949/3,121 Sec#190/266 |
| Op. Margin | -543.79% | US#2,808/3,121 Sec#155/266 |
| Revenue Growth | -67.95% | US#2,757/3,121 Sec#173/266 |
| Financial Health | ||
| Debt Ratio | 21.55% | US#247/3,121 Sec#85/266 |
| Total Debt | $17M | US#2,777/3,121 Sec#193/266 |
| FCF | $-237M | US#2,809/3,121 Sec#220/266 |
| Cash | $273M | US#1,487/3,121 Sec#86/266 |
| Current Ratio | 7.54x | US#337/3,121 Sec#104/266 |
| Performance | ||
| 1Y Return | 46.27% | US#616/3,121 Sec#115/266 |
| 1M Return | -2.97% | US#1,375/3,121 Sec#125/266 |
| From 52W High | -28.93% | US#2,005/3,121 Sec#157/266 |
| 1Y MDD | -27.97% | US#1,276/3,121 Sec#79/266 |
| Trading | ||
| Volume | 407,491 shares | US#2,190/3,121 Sec#224/266 |
| Trading Value | $4M | US#2,758/3,121 Sec#232/266 |
| Per Share | ||
| EPS | $-1.71 | US—/3,121 Sec—/266 |
| BPS | $3.43 | US#2,430/3,121 Sec#157/266 |